Related Experiment Video

Updated: Jul 3, 2026

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes
16:26

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Published on: August 20, 2007

Therapeutic management of posttransplant diabetes mellitus

Roslyn B Mannon1

  • 1Transplantation Branch, National Institutes of Diabetes and Digestive and Kidney Diseases, National Institute of Health, Bethesda, MD 20892, USA. rozm@mail.nih.gov

Transplantation Reviews (Orlando, Fla.)
|July 18, 2008
PubMed

Insights

Post-transplant diabetes mellitus is a common complication with multiple causes, including immunosuppression. Management involves various therapies, and vigilant screening is crucial for patient and graft outcomes.

Area of Science:

  • Nephrology
  • Endocrinology
  • Immunology

Background:

  • Diabetes mellitus is a frequent metabolic complication following solid organ transplantation.
  • Its development is multifactorial, influenced by modifiable and nonmodifiable factors.
  • Immunosuppression is a significant contributor to post-transplant diabetes mellitus (PTDM).

Purpose of the Study:

  • To review current understanding of PTDM etiology and risk factors.
  • To discuss established and novel therapeutic strategies for PTDM.
  • To emphasize the importance of vigilant screening and management in transplant recipients.

Main Methods:

  • Review of existing literature on PTDM in solid organ transplant recipients.
  • Analysis of treatment modalities, including oral hypoglycemics, insulin, and newer agents.
  • Discussion of the impact of PTDM on patient and graft outcomes.

Main Results:

  • PTDM etiology is complex, with immunosuppression playing a key role.
  • Treatment options range from traditional oral agents and insulin to newer FDA-approved therapies.
  • Limited data exists on the efficacy and safety of novel agents in transplant patients.

Conclusions:

  • Effective PTDM management is essential due to its negative impact on patient and graft survival.
  • Transplant practitioners must be proactive in screening for and managing PTDM.
  • Further research is needed on novel therapeutic agents in the transplant population.

More Related Videos

Transplantation of Pancreatic Islets Into the Kidney Capsule of Diabetic Mice10:43

Transplantation of Pancreatic Islets Into the Kidney Capsule of Diabetic Mice

Published on: October 31, 2007

Related Concept Videos

Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Kidney Transplant III: Nursing Management01:16

Kidney Transplant III: Nursing Management

Postoperative Nursing Management for Kidney Transplant PatientsPostoperative nursing management care includes monitoring the surgical site, encouraging early movement, and promoting lung health through breathing exercises. Nurses also administer prescribed medications like H2-blockers, such as famotidine, or proton pump inhibitors, like omeprazole, to help prevent gastrointestinal ulcers and bleeding. Fungal infections in the mouth and bladder can result from immunosuppressive and antibiotic...
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Kidney Transplant II: Surgical Procedure01:26

Kidney Transplant II: Surgical Procedure

Preoperative ManagementThe primary goals of preoperative management in kidney transplantation are to optimize the patient’s metabolic state and prepare them for surgery through diet adjustments, necessary dialysis, and tailored medical treatment. This phase also involves comprehensive infection screening and patient education about the surgical procedure and postoperative care to improve outcomes and adherence.Medical ManagementA comprehensive evaluation is required for both the living donor...